BioCentury
ARTICLE | Company News

Zymeworks, GSK in second antibody deal

April 27, 2016 1:14 AM UTC

Zymeworks Inc. (Vancouver, B.C.) granted GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) an option to license molecules developed using the biotech's Azymetric bispecific antibody discovery platform.

The companies partnered in December to develop mAbs and bispecific antibodies with optimized Fc domains using Zymeworks' Effector Function Enhancement and Control Technology (EFECT) platform. GSK now will be permitted to develop new antibodies using both platforms (see BioCentury Extra, Dec. 3, 2015). ...